Treatment Strategies and Immune Responses in Rheumatic Diseases
A special issue of Diseases (ISSN 2079-9721).
Deadline for manuscript submissions: 31 October 2024 | Viewed by 53
Special Issue Editor
Interests: autoimmune diseases; immunopathogenesis; B cells; T cells; autoantibodies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Rheumatic diseases are chronic inflammatory immune-mediated disorders that may affect the joints, muscles, and bones and that exhibit systemic and/or organ-specific involvement. These conditions can have a major impact on patients’ quality of life, society more broadly, and can represent an economic burden. Therefore, facilitating early diagnosis and providing adequate treatment are fundamental for effective disease management.
Treatment options in rheumatic disorders include the use of non-steroid anti-inflammatory drugs (NSAIDs), corticosteroids, synthetic and biological disease-modifying anti-rheumatic drugs (DMARDs). Synthetic DMARDs can be further classified as conventional DMARDs, such as methotrexate, or as targeted DMARDs, such as janus kinase (JAK)-inhibitors. Biological DMARDs include tumor necrosis factor (TNF)-inhibitors; the interleukin (IL)-6 receptor antagonist tocilizumab; the T-cell co-stimulation modulator abatacept; and the B-cell depleting agent rituximab.
Despite the progresses achieved in recent decades and the development of novel treatment strategies to effectively stop or attenuate the progression of rheumatic diseases, not all patients reach sustained remission and refractory disease remains a significant challenge.
The aim of this Special Issue is to collect original research articles and/or reviews that focus on the impact of treatment management and immune responses in rheumatic diseases and novel approaches in precision medicine.
Dr. Rita Aguiar Moura
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- rheumatic diseases
- disease-modifying anti-rheumatic drugs (DMARDs)
- immune responses
- precision medicine
